A new health care index predicts short term mortality for TB and HIV co-infected people.

Roen, A O; Podlekareva, D; Miller, R F; Mocroft, A; Panteleev, A; Skrahina, A; Miro, J M; Cayla, J A; Tetradov, S; Derisova, E; Furrer, H; Losso, M H; Vassilenko, A; Girardi, E; Lundgren, J D; Post, F A; Kirk, O (2020). A new health care index predicts short term mortality for TB and HIV co-infected people. The international journal of tuberculosis and lung disease, 24(9), pp. 956-962. IUATLD 10.5588/ijtld.19.0568

[img] Text
Roen_HealthCareIndexHIVTBCoinfection_IJTLD 2020_24_956.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (223kB) | Request a copy

BACKGROUND: Using 2004-2007 TB:HIV Study data<x/> from Europe and Latin America, we previously generated a health care index (HCI) for TB and HIV co-infected people. With improvements in diagnostic and management practices, we have now updated the HCI with new data.METHODS: We evaluated nine aspects of health care in Cox proportional hazards models on time from TB diagnosis to death. Kaplan-Meier methods were used to estimate the probability of death by HCI quartile.RESULTS: Of 1396 eligible individuals (72% male, 59% from Eastern Europe), 269 died within 12 months. Use of rifamycin/isoniazid/pyrazinamide-based treatment (HR 0.67, 95% CI 0.50-0.89), TB drug susceptibility testing (DST) and number of active TB drugs (DST + <3 drugs (HR 1.09, 95% CI 0.80-1.48), DST + ≥3 drugs (HR 0.49, 95% CI 0.35-0.70) vs. no DST), recent HIV-RNA measurement (HR 0.64, 95% CI 0.50-0.82) and combination antiretroviral therapy use (HR 0.72, 95% CI 0.53-0.97) were associated with mortality. These factors contributed respectively 5, -1, 8, 5 and 4 to the HCI<x/>. Lower HCI was associated with an increased probability of death; 30% (95% CI 26-35) vs. 9% (95% CI 6-13) in the lowest vs. the highest quartile.<x/>CONCLUSION: We found five potentially modifiable health care components that were associated with mortality among TB-HIV positive individuals. Validation of our HCI in other TB cohorts could enhance our findings.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Furrer, Hansjakob


600 Technology > 610 Medicine & health








Annelies Luginbühl

Date Deposited:

09 Dec 2020 16:27

Last Modified:

05 Dec 2022 15:42

Publisher DOI:


PubMed ID:






Actions (login required)

Edit item Edit item
Provide Feedback